The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
GSK getting their finances topped up for drug pipeline đ¤
https://www.dailymail.co.uk/money/markets/article-12972855/GSK-sells-978m-stake-Haleon-drugmaker-cuts-holding-4-2.html
Https://www.japantimes.co.jp/commentary/2023/12/29/world/targeted-cancer-drugs/
"Targeted cancer drugs finally live up to the hype"
Read on.....
RNS !
From RBS.
"The continuing success of AVA6000 in the Phase 1a clinical study is important not only for the potential to improve outcomes for patients with cancers suitable for treatment with doxorubicin, but also as a validation of the pre|CISIONTM platform more widely. The Company aims to complete the AVA6000 three-weekly dose escalation safety study and to provide a detailed data read-out during Q4 2023."
So anytime !
Thanks for all the great input this week.
Enjoy the rugby and the weekend
AVACTA TO PRESENT PROMISING NEW DATA
05 Oct 2023
Avacta to present promising new data from AffimerÂŽ and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
AVA3996: FAP-Îą-activated proteasome inhibitor from pre|CISIONTM platform concentrates proteasome inhibitor payload in the tumour, increasing the therapeutic index of this class of drugs
AVA032: anti-PD-L1 AffimerÂŽ fused to IL-15 demonstrates encouraging in vitro and in vivo efficacy
Avacta Group plc (AIM: AVCT), a life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics, today announces that it will be presenting two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place on 11-15 October 2023 in Boston Massachusetts.
Details of the poster presentations are as follows:
Abstract title:AVA3996, a novel pre|CISION⢠medicine, targets a warhead to the tumor microenvironment via Fibroblast Activation Protein (âFAPâ) mediated cleavage to elicit tumor cell kill
Poster number: C169
Session: Poster Session C
Session date and time: Saturday, October 14 | 12:30 pm-4:00 pm
Session location: Level 2, Exhibit Hall D
Abstract title:A novel, tumor-targeted immunocytokine comprising an anti-PD-L1 AffimerÂŽ fused to IL-15 exhibits potent anti-tumor activity
Poster number: A077
Session: Poster Session A
Session date and time: Thursday, October 12 | 12:30 pm-4:00 pm
Session location: Level 2, Exhibit Hall D
Dr Fiona McLaughlin, Chief Scientific Officer of Avacta commented:
âWe look forward to presenting the promising new data from Avactaâs Therapeutics platform assets at this conference. As disclosed in the Companyâs announcement on 19 September 2023, our lead asset AVA6000 continues to advance through the clinic at pace. We are simultaneously conducting IND-enabling studies for promising assets derived from the pre|CISIONTM and AffimerÂŽ platforms. The data to be presented showcases the potential of our two therapeutic platforms to generate further high value clinical assets.
20 September 2023
Avacta Group plc
("Avacta" or the "Group" or the "Company")
Appointment of Dr. Christina Coughlin as a consultant
Related party transaction notification
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that, according to the AIM rules governing Related Party Transactions, that it has entered into a consultancy agreement with Dr. Christina Coughlin (the "Consultancy Agreement"), currently a Non-Executive Director of the Group, as it seeks to appoint a full-time Chief Medical Officer.
The continuing very positive clinical progress of AVA6000 has validated the tumour targeting capability of the pre|CISIONTM platform. This has opened up the potential for multiple commercial opportunities, and the scope for using pre|CISIONTM to create a pipeline of new tumour-targeted cancer therapies is extensive. The Company's clinical strategy is key to fully exploiting this opportunity through a combination of in-house development and an active licensing and commercial partnerships programme. Therefore, the Company is seeking to add a full-time Chief Medical Officer (CMO) with responsibility for driving the Company's clinical strategy.
In advance of appointing a full-time CMO, the Company will leverage the expertise of Dr. Coughlin on a temporary basis through the Consultancy Agreement. Dr. Coughlin is a highly experienced clinical oncologist with a broad background in biotechnology, global pharmaceuticals, and comprehensive experience in drug development from pre-IND to filing. Dr Coughlin also has a proven track record of building drug development teams in global companies.
Dr. Coughlin, M.D., Ph.D. was previously the Chief Executive Officer of Cytolmmune Therapeutics LLC, a clinical-stage biotechnology company, focused on the development and commercialisation of novel cancer immunotherapy products designed to use the patient's own immune system to eliminate cancer cells. She also served as Chief Medical Officer to Rubius Therapeutics. Inc, where she led the clinical development, translational medicine and regulatory efforts in the allogeneic red cell therapy platform. Prior to Rubius, Dr. Coughlin was with Tmunity Therapeutics, Inc., where she served as Chief Medical Officer and was responsible for the development of autologous CAR-T and TCR-T cellular therapies.
Dr. Coughlin will retain her position on the Avacta Board as a Non-Executive Director.
Avacta also announces that Neil Bell, Chief Development Officer of the Group, will be leaving the Company. Under Neil's guidance over the last three years, the Company has established a clinical development infrastructure which will help support the Company's clinical programmes going forwards. Avacta wishes him well in the future.
Under the terms of the Consultancy Agreement, Avacta will pay Dr Coughlin a monthly con
Had a sign from the big man in the sky.....
Stoke citys next signing ?
Check out the shirt sponsor đ
https://www.stokesentinel.co.uk/sport/football/football-news/stoke-city-transfer-wouter-burger-8699964
This is 100% of my portfolio and I'm supremely confident after the latest piece of information that this is the real deal.
Still a long way to go but now looking forward to more great news
Well done Kenyan.....
Loving the speed of communication's now.
All very positive
The animation is awesome....
https://avacta.wistia.com/medias/57q8yebuy6
From Dec RNS :
Avacta to Host Therapeutics Division Science Day on 23rd February 2023
Science Day to include presentation of the data emerging from the phase 1a clinical trial of AVA6000
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will host a Science Day for City analysts and fund managers on 23rd February 2023 to discuss recent progress within the Companyâs Therapeutics Division and hear from selected key opinion leaders in the field of oncology.
The event will include an update on the ongoing preclinical programmes as well as on progress in the ALS-6000-101 phase 1a clinical trial of AVA6000, Avactaâs lead pre|CISIONTM tumour targeted chemotherapeutic, a modified form of the chemotherapy doxorubicin.
Sit on your hands knowing that a deal or licence is on the cards.....a little bit of patience will be rewarding.
JAWDROP draws the best Life Science academics, startups, scaleups, enterprise & investors.
Explore, hear & meet the changemakers.
WCID is fast emerging as a global economic hotspot in science, technology, engineering, mathematics, medicine, business (STEMMB), the arts and media.
This Life Sciences symposium has grown out of the thriving Deep Tech Network (DTN) set up by Imperial College London and Upstream in 2019. The DTN aims to encourage interaction and collaboration between business and academia and develop a deep-tech innovation ecosystem around Imperialâs White City Campus.
The summit will allow industry and academia to share their work in an in-depth manner with an audience of leading scientists, technologists, researchers and decision makers from across White City and other UK ecosystems.
https://www.whitecityinnovationdistrict.org.uk/jawdrop-summit/
If you look at the timing of the last 20 or so Rand's you will see that quite a number of them are NOT at 7am.....
So be alert
BetulaKapital - thank you for the information.
It was a real opener.
Wishing you and all Avacta staff + cancer sufferers and all of the share holders a very happy and prosperous new year
Wishing Peace for the world
This showed doctors he may potentially have a good response to the treatment.
Mr Glynn was started on an immunotherapy drug, which is already approved for use in other cancers, including lung, kidney and oesophageal cancer.
The treatment, which is given by a drip and helps a personâs own immune system fight cancer, was combined with standard chemotherapy.
The drug cannot be named due to the experimental nature of this trial for bile duct cancer.
To his surprise, the tumour in his liver had shrunk from 12cm to 2.6cm, while his adrenal gland tumour went from 7cm to 4.1cm.
This meant Mr Glynn was able to undergo surgery in April to finally remove them.
Surgeons found only dead tissue, which meant the treatment had killed off all the cancer cells.
Since his operation, he has not needed any more treatment and his three-monthly scans show he is clear of cancer.
Regardless, Mr Glynn is doing his best to live a healthier lifestyle and has changes his diet completely.
âI cut out processed foods, refined sugar, dairy and milk and now have a smoothie every day and organic fruit and vegetables and make everything from scratch,â he said.
âI managed to lose 5st, which was a big step for me. I realised you cannot just rely on the doctors to help you. You need to help yourself too.
âItâs also important to remain positive and not give up. Itâs never over until itâs over.â
The clinical trial was run by Professor Juan Valle, consultant oncologist at the Christie and a world-leading expert in biliary tract cancer.
Robert Glynn, from Worsley, in Greater Manchester, was diagnosed with bile duct cancer a day before his 49th birthday, during the height of the Covid pandemic.
He had visited his GP, undergoing a series of scans and blood tests but his cancer was only picked up by chance when he got an infection in his gall bladder.
Also known as biliary tract cancer, it is a rare form with just few treatment options.
Only around 1,000 people in the UK are diagnosed with it every year and just 5% of them live for five years or more after diagnosis.
But the welder was referred to Christie NHS Foundation Trust to take part in a new clinical trial of immunotherapy.
The now 51-year-old said: âI wouldnât be here today without the trial. When I was given the option to take part in research, I jumped at the chance.
âYou do anything you can to extend your life. I feel very lucky as I had the cancer for two years and had no idea.
âSo getting the all-clear was overwhelming. Having the diagnosis has turned my life around.
âWith my partner, Simone, we get out in nature and walk loads. When something like this happens you realise life is for living.â
Before starting the trial, his tumour was analysed for any genetic alterations, and the results showed he had a high mutation burden (large numbers of genetic mutations in the cells).